Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1056426.RAV-a-F_YIg00imqrezi_nIUlC7NzWc_bpDJ-7wL326wk130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1056426.RAV-a-F_YIg00imqrezi_nIUlC7NzWc_bpDJ-7wL326wk130_assertion type Assertion NP1056426.RAV-a-F_YIg00imqrezi_nIUlC7NzWc_bpDJ-7wL326wk130_head.
- NP1056426.RAV-a-F_YIg00imqrezi_nIUlC7NzWc_bpDJ-7wL326wk130_assertion wasGeneratedBy ECO_0000203 NP1056426.RAV-a-F_YIg00imqrezi_nIUlC7NzWc_bpDJ-7wL326wk130_provenance.
- NP1056426.RAV-a-F_YIg00imqrezi_nIUlC7NzWc_bpDJ-7wL326wk130_assertion wasDerivedFrom befree-2016 NP1056426.RAV-a-F_YIg00imqrezi_nIUlC7NzWc_bpDJ-7wL326wk130_provenance.
- NP1056426.RAV-a-F_YIg00imqrezi_nIUlC7NzWc_bpDJ-7wL326wk130_assertion SIO_000772 23445613 NP1056426.RAV-a-F_YIg00imqrezi_nIUlC7NzWc_bpDJ-7wL326wk130_provenance.
- NP1056426.RAV-a-F_YIg00imqrezi_nIUlC7NzWc_bpDJ-7wL326wk130_assertion evidence source_evidence_literature NP1056426.RAV-a-F_YIg00imqrezi_nIUlC7NzWc_bpDJ-7wL326wk130_provenance.
- NP1056426.RAV-a-F_YIg00imqrezi_nIUlC7NzWc_bpDJ-7wL326wk130_assertion description "[These findings create a compelling rationale to determine the in vivo activity of dual PI3K/mTOR inhibitors in combination with JAK inhibitors against myelofibrosis HPCs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1056426.RAV-a-F_YIg00imqrezi_nIUlC7NzWc_bpDJ-7wL326wk130_provenance.